Company Insights

SNOA customer relationships

Explore interactive graphBrowse insights index

SNOA customers relationship map

Sonoma Pharmaceuticals (SNOA): Customer Relationships and Commercial Footprint

Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid (HOCl) products and monetizes through direct product sales, manufacturing and supply agreements, licensing arrangements, and laboratory services. The company sells branded and white‑label HOCl wound, dermatology and consumer products into retail chains, hospital systems and international distributors while also licensing its Microcyn® technology to partners for co‑branded or exclusive channels. Revenue mix is therefore a hybrid of direct sales, contract manufacturing, and licensing fees, with retail rollouts and strategic supply deals driving recent growth. For more background on Sonoma’s commercial scope visit https://nullexposure.com/.

Quick read: the investment angle

  • Retail rollout and manufacturing partnerships are expanding reach into mass retail (Walmart, CVS), e‑commerce (Amazon) and large healthcare distributors (Medline).
  • Contracting posture is multi‑modal: master sales agreements and licensing relationships enable scale without proportional capex.
  • Geographic diversification is meaningful—Sonoma reports sales across North America, EMEA, LATAM and APAC—reducing single‑market concentration but preserving reliance on a subset of larger customers.

How Sonoma gets paid: model and commercial mechanics

Sonoma operates as a product manufacturer, contract manufacturer and licensor. It sells finished goods under its own brands and under partner brands, enters manufacturing and supply agreements for large consumer healthcare companies, and licenses technology where partners handle distribution. The company also earns service revenue from laboratory testing for medical device manufacturers. This blended model supports low fixed‑cost scaling through partner distribution while preserving margin capture on owned SKUs.

Second CTA (mid‑article): For proprietary signals and relationship monitoring consult https://nullexposure.com/.

Operating model and constraints that matter to investors

Sonoma’s customer relationships are governed by a mix of master sales agreements and purchase orders, with explicit licensing arrangements for its Microcyn® technology. Company disclosures describe framework contracts (“master sales agreements”) as the governing construct for certain customer orders and confirm the presence of licensing agreements for technology and product rights. Sonoma sells directly to hospitals and healthcare practitioners while also using non‑exclusive distributors and resellers, which indicates a mixed sales channel strategy combining direct B2B and wholesale/retail B2C flows.

Geography is a structural feature of the business: Sonoma reports sales across 55 countries and line‑items revenue by region (United States, Europe, Latin America, Asia). Management flags reliance on key customers for a significant portion of revenue, which signals customer concentration risk even as the firm expands retail distribution. Relationship roles in company filings include licensor, service provider (laboratory testing), distributor and seller/reseller—illustrating a multi‑role commercial posture that supports both licensed royalties and product sales.

Who Sonoma is selling to — relationship by relationship

Walmart (WMT)

Sonoma launched HOCl‑based infant diaper‑rash products into Walmart and other U.S. retailers in August 2025 and followed with a burn relief hydrogel and wound care SKUs rolled into Walmart stores nationwide; the antimicrobial hydrogel is now available in 3,600 Walmart locations. Source: BizWest coverage of FY2025 product launches (Nov 6, 2025) and Investing.com summary of SEC filings (May 2026).

Amazon.com (AMZN)

Sonoma’s antimicrobial hydrogel and consumer SKUs are sold through Amazon, expanding the company’s e‑commerce footprint alongside brick‑and‑mortar retail launches. Source: Investing.com SEC filing summary reporting product availability online (May 2026).

Persōn & Covey, Inc.

Sonoma developed the Aquanil® AD dermatology line exclusively for Persōn & Covey for distribution through Persōn & Covey’s over‑the‑counter dermatology channels in the U.S., reflecting a white‑label/manufacturer relationship with exclusive product design for the partner. Source: Persōn & Covey press release syndications and Sonoma press materials (announced FY2026, multiple press outlets March–May 2026).

Medline Industries, LP (Medline / MDLN)

Sonoma entered a manufacturing relationship to produce an HOCl wound cleanser for Medline, with distribution planned into hospital systems, home health and other healthcare channels across the U.S. and Canada—representing a channel partnership with a major healthcare supplier. Source: Sonoma press release and AccessNewswire/FY2025–FY2026 coverage (Oct 2025 / Mar–May 2026).

CVS (CVS)

Sonoma launched its advanced HOCl burn relief hydrogel into CVS stores nationwide as part of a coordinated U.S. retail rollout that also included Walmart, giving Sonoma placement in a leading pharmacy chain. Source: AccessNewswire retail launch announcement (FY2026).

Kenvue Brands LLC (Kenvue / KVUE)

Sonoma entered a Manufacturing and Supply Agreement with Kenvue Brands to sell Microcyn® technology‑based products in the U.S., positioning Sonoma as a contract manufacturer and supplier to a global consumer health company. Source: Marketscreener and Investing.com reporting on the Manufacturing and Supply Agreement (FY2026).

Te Arai BioFarma

Sonoma’s product availability in Oceania is facilitated through Te Arai BioFarma, which distributes Sonoma’s urinary tract and related products in New Zealand and Australia, demonstrating regional partnership distribution for specialty indications. Source: Yahoo Finance coverage of regional partner distribution (FY2022).

NuAngle

Sonoma lists NuAngle as a distribution partner for South Africa, reflecting targeted local partnerships to extend international reach for specialized HOCl formulations. Source: Yahoo Finance regional distribution note (FY2022).

What these relationships mean for investors

  • Retail placements (Walmart, CVS, Amazon) accelerate volume and brand visibility but expose Sonoma to retail slotting dynamics and promotional pressure.
  • Large supply agreements (Kenvue, Medline) convert manufacturing capacity into recurring channel sales and reduce go‑to‑market expense per unit, improving leverage as volumes scale.
  • Exclusive co‑developed brands (Persōn & Covey) diversify revenue streams into partner‑branded channels and validate Sonoma’s contract‑manufacturing and formulation capabilities.
  • International distributor partners (Te Arai, NuAngle) provide market entry without large local investment, supporting reported sales across APAC, EMEA and LATAM.

Final view and risks to monitor

Sonoma’s customer mix reflects a deliberate strategy to combine branded product growth with contract manufacturing and licensing, increasing both revenue diversity and distribution scale. Key risks include customer concentration with several large counterparties, margin pressure from retail placement and reseller return privileges, and execution risk in scaling manufacturing to meet multiple large partner agreements. Investors should monitor quarterly disclosures for contribution by channel (retail vs. manufacturing) and any updates to master sales agreements or licensing terms.

For continuous tracking of Sonoma’s commercial relationships and partner disclosures visit https://nullexposure.com/.

Join our Discord